Isotopia
- Company typePrivate
- Founded2012
- HeadquartersPetah Tikwah, Israel
- Headcount51–100
- GTM typeB2B
- OfferingHardware or Manufacturing
What Isotopia does
Isotopia Molecular Imaging Ltd. is an Israel-based radiopharmaceutical company that develops, manufactures, and distributes medical radioisotopes and radiopharmaceutical products for diagnostic imaging and targeted radionuclide therapy. Founded in 2012 as a collaboration between The Metrontario Group and Israeli scientists, the company is headquartered in Petach Tikva, Israel with 51–100 employees, and operates GMP-certified aseptic manufacturing across Petach Tikva and a newly relocated 2,000+ sqm facility in Modiin. It holds the first GPP-certified nuclear pharmacy in Israel and has cleared FDA inspection with a Drug Master File filed for non-carrier-added Lutetium-177.
Isotopia firmographics
Firmographics- Name
- Isotopia
- Legal name
- Isotopia Molecular Imaging Ltd.
- Website
- https://isotopia-global.com
- Company type
- Private
- Founded year
- 2012
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Ownership category
- akta.pro rank
Isotopia industry classification
Industry- Product category
- Radiopharmaceuticals
- NAICS
- Pharmaceutical and Medicine Manufacturing (3254), In-Vitro Diagnostic Substance Manufacturing (325413), Medical Equipment and Supplies Manufacturing (3391)
- SIC
- In Vitro & In Vivo Diagnostic Substances (2835), Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx) (HLAIAGAC)
- akta.pro secondary industries
- Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy) (HLAIAGAB), Diagnostic Radiopharmaceuticals (SPECT/PET Tracers) (HLAIAGAA), Radioisotope Production (Reactor/Cyclotron/Gamma) (HLAIAGAD), Radiopharmacy Compounding & Dispensing (Hospital/Commercial) (HLAIAGAE), Medical Radioisotope Production (Reactor/Cyclotron, Mo-99/Tc-99m, I-131, Lu-177, etc.) (EUAKAIAA)
Keywords
Where Isotopia is headquartered
LocationHeadquarters
- HQ city
- Petah Tikwah
- HQ country
- Israel
- HQ region
- Middle East
Offices3 records
Markets served
Isotopia business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Operations, Supply Chain, Technology or R&D, Infrastructure, Marketing or Sales
Revenue model
- Radioisotope Product Sales: Sale of medical radioisotopes including Lutetium-177 (c.a. and n.c.a.), Terbium-161, and Gallium-68 to pharmaceutical companies, hospitals, and nuclear medicine departments for diagnostic imaging and targeted radionuclide therapy.
- Radiopharmaceutical Cold Kits: Sale of ready-to-use radiolabeling kits including Isoprotrace (Ga-68 PSMA-11) for prostate cancer imaging and cold kits for radiopharmaceutical preparation.
- Contract Manufacturing Organization (CMO) Services: Aseptic manufacturing and fill-finish services for sterile drug preparations, cold kits, and radiopharmaceuticals for pharmaceutical partners. Services include product development, quality control, and regulatory support.
- Clinical Supply Agreements: Supply of radioisotopes for clinical trials under GMP conditions to pharmaceutical companies developing radiopharmaceutical therapies. Long-term supply contracts ensuring 52 weeks per year production capacity.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | GMP-certified radioisotopes and radiopharmaceuticals |
Go-to-market motion3 records
Distribution channels12 records
Marketing channels10 records
Isotopia product offering
Product offeringCore offering
Isotopia develops, manufactures, and distributes diagnostic and therapeutic radiopharmaceuticals used in nuclear medicine and molecular imaging. Core offerings include Lutetium-177 (both carrier-added and non-carrier-added forms) for targeted radionuclide therapy, Terbium-161 as a next-generation therapeutic isotope, the Isoprotrace® Gallium-68 PSMA-11 radiolabeling kit for prostate cancer PET imaging, and F-18 DOPA PET tracers. The company also operates a GMP-certified aseptic manufacturing facility providing contract manufacturing (CMO) services for sterile radiopharmaceutical and injectable preparations.
Product overview
Isotopia is a global radiopharmaceutical company offering a comprehensive portfolio of diagnostic and therapeutic products for nuclear medicine. The core offerings include: Isoprotrace® (Gallium-68 PSMA-11 radiolabeling kit for prostate cancer PET imaging), Lutetium-177 (both n.c.a. and c.a. forms for targeted radionuclide therapy), and Terbium-161 (next-generation therapeutic isotope). Supporting products include PET and SPECT radiopharmaceuticals, cold kits, and calibration sources. The company operates manufacturing facilities in Israel (Petah Tikva and Modiin) providing aseptic manufacturing and CMO services for sterile drug production. Isotopia serves pharmaceutical companies and healthcare providers globally with production capabilities spanning from Israel to partnerships in North America, Europe, and Asia.
Differentiator
Problem solved
Functional benefit
Products and services
- Isoprotrace® Ready-to-use, multi-dose radiolabeling kit for preparation of Gallium-68 Gozetotide (68Ga-PSMA-11) used in PSMA PET/CT imaging of prostate cancer. Enables 1-vial, 1-step preparation with >95% radiochemical purity and approximately 5-minute preparation time.
- Lutetium-177 (Lu-177) — n.c.a. and c.a. Therapeutic radioisotope supplied in both non-carrier-added (n.c.a.) and carrier-added (c.a.) forms as GMP-grade Lu-177 chloride. N.c.a. Lu-177 contains no metastable Lu-177m impurities, eliminating cost-intensive clinical waste management. Used in targeted radionuclide therapy for neuroendocrine tumors and prostate cancer.
- Terbium-161 Next-generation therapeutic radioisotope emitting both beta radiation and Auger electrons for targeted cancer treatment. Developed using Gadolinium-160 target material, with advantages over Lu-177 for targeting micrometastases. Used in clinical trials for prostate cancer and neuroendocrine tumors.
- F-18 DOPA PET radiotracer (Fluorine-18 DOPA) for imaging dopaminergic neurons in the brain and detection of neuroendocrine tumors. Used for evaluation of Parkinsonian syndromes and diagnosis of neuroendocrine tumors including pheochromocytoma, paraganglioma, neuroblastoma, and infant insulinemia.
- PET Radiopharmaceutical Products Portfolio of PET (Positron Emission Tomography) radiopharmaceuticals including F-18 DOPA for neuroendocrine tumors and Parkinson's disease diagnosis, and Ga-68 based tracers for diagnostic imaging.
- SPECT Radiopharmaceutical Products Single Photon Emission Computed Tomography (SPECT) radiopharmaceutical products for diagnostic imaging across various clinical applications.
- Cold Kits Radiopharmaceutical cold kits for convenient preparation of diagnostic tracers in clinical settings, including kits for Ga-68 radiolabeling and other isotopes used in nuclear medicine imaging.
- Lu177 Treatment Services Radiopharmaceutical treatment preparations based on Lutetium-177 for targeted radionuclide therapy of cancers including neuroendocrine tumors and prostate cancer.
- Aseptic Manufacturing / CMO Services
Quantifiable outcome
- 68Ga-PSMA PET/CT demonstrated 92% accuracy compared to 65% accuracy for conventional CT and bone scan imaging in prostate cancer staging
- +2 more outcomes
Companies that use Isotopia
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Isotopia technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration3 records
Feature5 records
Isotopia partnerships and signals
Strategic signalPartnerships
19 partnerships are on record, tiered regional, core, minor and foundational.
- M.G.P. spol. s r.o. (Czech Republic)regionalOfficial distributor for Isoprotrace in the Czech Republic providing comprehensive nuclear medicine solutions from imaging equipment to radiopharmaceuticals.
- Peter MacCallum Cancer Centre (ProsTIC)coreClinical research and supply agreement for n.c.a. Tb-161 for first-in-human pilot study. Prostate Cancer Theranostics and Imaging Centre of Excellence (ProsTIC) will conduct trial linking 161Tb to PSMA for advanced prostate cancer treatment.
- Sinotau PharmaceuticalscoreStrategic collaboration for supply of n.c.a. 177Lu to support Sinotau's clinical development pipeline in China. Sinotau has manufacturing sites in Jiangsu, Guangdong, Sichuan with plans for commercialization.
- Seibersdorf Labor GmbHcoreProduction agreement for 177Lu n.c.a. at Austria facility. Selected after year-long evaluation for high GMP infrastructure and expertise. Expected commercial-scale production by Q4 2022 with easy land transport access to European market.
- HERMES Medical SolutionsminorCollaboration focused on dosimetry and personalized medicine. HMS provides quantitative imaging and dosimetry software expertise while Isotopia contributes radiopharmaceutical innovation. Joint development of dosimetry tools for Tb-161 therapeutic isotope.
- POINT BiopharmacoreClinical supply agreement for n.c.a. Lu-177 for use in POINT's PNT2002 PSMA-targeting drug for mCRPC. Lu-177 will be used at POINT's Indianapolis facility for clinical trials including Phase 3 SPLASH trial.
- Bar-Ilan UniversityminorResearch collaboration with Prof. Sharon Ruthstein to develop hypoxia radioactive marker based on Copper-64 isotope for detecting oxygen-deficient cells and tumor aggressiveness. Part of Innovation Authority's Magneton Program.
- Elgan PharmaminorStrategic agreement for Phase III and commercial CMO services for lyophilized product manufacturing. Isotopia provides sterile production with high GMP compliance for Elgan's neonatology therapies.
- Jubilant RadiopharmacoreStrategic commercial partnership with exclusive license to market Isotopia's theranostic products in the US. Combines Isotopia's innovation with Jubilant's 49-radiopharmacy network for North American market expansion.
- M.T.T.I (Molecular Targeting Technologies)coreClinical supply agreement for n.c.a. 177Lu to support development of 177Lu-EBTATE for neuroendocrine tumors and 177Lu-EBRGD for GBM and NSCLC using Evans Blue platform technology.
- ARTMScoreTechnology partnership for multi-curie radiolabeling of PSMA-11 with cyclotron-produced Ga-68 using ARTMS' Quantum Irradiation System (QIS). Successful labeling with 500-2900 mCi of 68Ga demonstrating 6-hour stability.
- Y-mAbs TherapeuticscoreClinical supply collaboration for n.c.a. 177Lu to support development of 177Lu-DTPA-omburtamab for B7-H3 positive CNS and leptomeningeal metastasis treatment.
- CPDC (Centre for Probe Development and Commercialization)coreProduction and distribution partnership for n.c.a. Lu-177 in North America. CPDC produces Lu-177 at Hamilton, Ontario facility. Expansion planned to NuGeneris Specialty Pharmaceuticals for commercial-scale production.
- Eckert & ZieglercoreDevelopment partnership to finalize PSMA-11 Kit development for prostate cancer imaging. Collaboration to make operation feasible on E&Z's KitLab with GalliaPharm 68Ge/68Ga generator in the DMF and EU marketing authorization.
- CNIC (Canadian Nuclear Isotope Council)foundationalGlobal partnership to ensure reliable and secure supply of life-saving medical isotopes. CNIC is an independent body representing Canadian health sector, nuclear industry, and research groups. Supports Isotopia's mission to develop and manufacture radiopharmaceutical treatments for patients globally.
- DSD Pharma (Germany)regionalOfficial commercial launch partner for Isoprotrace in Germany with marketing authorization.
- Cardirad (Sweden and Denmark)regionalDistribution partner for Isoprotrace launch in Sweden and Denmark expanding Nordic market access.
- Immunity Pharma Ltd (IPL)minorStrategic agreement for clinical contract manufacturing services.
- Isotopia USA (E Solutions and Comfort Systems)regionalUS market partnerships for operations and distribution support.
Scale indicators5 records
Recent moves7 records
Expansion highlights4 records
Isotopia competitors and assessment
Company assessmentBroad incumbents
- GE HealthCare: Global incumbent offering a broad radiopharma portfolio (SPECT/PET tracers, contrast media) plus PETNET Solutions radiopharmacy network. Operates at much greater scale and overlaps with Isotopia across diagnostic imaging tracers and radiopharmacy distribution.
- PETNET Solutions (Siemens Healthineers): Operates a large network of PET radiopharmacy sites producing FDG and other PET tracers across the US and Europe. Directly comparable to Isotopia's PET/SPECT radiopharmacy and cold kit business.
- Cardinal Health (Nuclear Pharmacy Services): Operates one of the largest US radiopharmacy networks distributing nuclear medicine products to hospitals. Comparable to Jubilant (Isotopia's exclusive US partner) and competes in the same downstream distribution layer.
- Bracco Imaging: Global diagnostic imaging company with a meaningful radiopharmaceutical and contrast media portfolio. Overlaps with Isotopia in nuclear medicine diagnostic products and shares pharmaceutical/hospital channels.
- Bayer (with Curium): Bayer's radiopharma franchise (including Xofigo, Ra-223 dichloride) is supplied in partnership with Curium, making it both a competitor and a comparable end-customer class for therapeutic radioisotope suppliers like Isotopia.
Direct peers
- Novartis (Advanced Accelerator Applications / AAA): Owns Pluvicto (Lu-177 vipivotide) and Lutathera, the leading Lu-177-based radioligand therapies, and operates large-scale Lu-177 production. A direct vertical competitor and a customer class for Isotopia's Lu-177 supply (Novartis also sources externally).
- Curium Pharma: One of the world's largest nuclear medicine companies, producing SPECT/PET diagnostic and therapeutic radiopharmaceuticals including Mo-99/Tc-99m and Lu-177. Directly competes with Isotopia in the Lu-177 supply market and shares the same pharma customer base.
- Lantheus Holdings: Diagnostic radiopharmaceutical company focused on PET and SPECT tracers, including Pylarify (piflufolastat F-18, a direct PSMA PET competitor to Isotopia's Isoprotrace Ga-68 PSMA-11 kit). Comparable in prostate cancer imaging focus.
- Telix Pharmaceuticals: Theranostic-focused radiopharma company developing Lu-177-based therapies (TLX591, TLX592) and Illuccix (Ga-68 PSMA-11 kit) — the latter is a direct head-to-head competitor to Isotopia's Isoprotrace product.
- ITM Isotope Technologies Munich: European producer of medical radioisotopes including Lu-177 and radiopharmaceutical kits for targeted radionuclide therapy. Direct competitor in the Lu-177 supply market with similar theranostics focus and GMP-certified production.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Isotopia social profiles
Digital presenceIsotopia compliance and trust
Trust signalCompliance5 records
Isotopia financial estimates
Financial estimateRevenue estimate
Valuation estimate
Isotopia leadership team
Management profileNumber of profiles
Profiles9 records
Isotopia funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Isotopia M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Isotopia
What does Isotopia do?
Isotopia develops, manufactures, and distributes diagnostic and therapeutic radiopharmaceuticals used in nuclear medicine and molecular imaging. Core offerings include Lutetium-177 (both carrier-added and non-carrier-added forms) for targeted radionuclide therapy, Terbium-161 as a next-generation therapeutic isotope, the Isoprotrace® Gallium-68 PSMA-11 radiolabeling kit for prostate cancer PET imaging, and F-18 DOPA PET tracers. The company also operates a GMP-certified aseptic manufacturing facility providing contract manufacturing (CMO) services for sterile radiopharmaceutical and injectable preparations.
Is Isotopia a public or private company?
Isotopia is a private company. It is classified as corporate owned and is currently operating.
When was Isotopia founded?
Isotopia was founded in 2012. It employs 51 to 100 people.
Where is Isotopia based?
Isotopia is headquartered in Petah Tikwah, Israel, in the Middle East region.
How does Isotopia make money?
Four revenue lines are on record. Radioisotope Product Sales are the primary driver. The others are radiopharmaceutical Cold Kits, contract Manufacturing Organization (CMO) Services and clinical Supply Agreements.
Who are Isotopia's main competitors?
Broad incumbents on record are GE HealthCare, PETNET Solutions (Siemens Healthineers), Cardinal Health (Nuclear Pharmacy Services), Bracco Imaging and Bayer (with Curium). Direct peers are Novartis (Advanced Accelerator Applications / AAA), Curium Pharma, Lantheus Holdings, Telix Pharmaceuticals and ITM Isotope Technologies Munich.
Does Isotopia have an API?
No public API is recorded for Isotopia.
What industry is Isotopia in?
Isotopia's product category is Radiopharmaceuticals. Its primary akta.pro industry code is HLAIAGAC, Theranostic Radiopharmaceutical Platforms (Paired Dx/Tx), with a secondary code of HLAIAGAB, Therapeutic Radiopharmaceuticals (Radioligand/Targeted Radionuclide Therapy). Its NAICS code is 3254 and its SIC code is 2835.